Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

A look at the shareholders of Pfizer Inc. (NYSE:PFE) can tell us which group is most powerful. The group holding the most ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Pfizer (PFE) ended the recent trading session at $25.35, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14%.

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

View the latest Pfizer Inc. (PFE) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

This was the stock's third consecutive day of losses.

A few weeks back, we discussed that Pfizer’s (NYSE: PFE) stock price could rebound over a one-month period after falling 4% in a week, based on its historical performance. However, PFE stock has ...

The Zacks Consensus Estimate for PFE’s 2025 sales implies a year-over-year decrease of 0.6% and 1%, respectively. EPS estimates for both 2025 and 2026 have risen over the past 60 days.